SCHEMBL30482175

SCHEMBL30482175

CC(=O)c1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 2/20 0.50
CES2 O00748 2/20 0.50
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
HSD17B10 Q99714 2/20 0.49
USP2 O75604 1/20 0.49
CYP2C19 P33261 1/20 0.49
AVPR2 P30518 1/20 0.47
GPR27 Q9NS67 1/20 0.47
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
TYK2 P29597 1/20 0.47
CFTR P13569 1/20 0.46
SORT1 Q99523 1/20 0.45
PDK2 Q15119 1/20 0.44
SMO Q99835 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6495907 1.00 PDE2A (0.50) PDE2ACES2KDM4EALDH1A1HPGD
SCHEMBL13801463 0.86 AVPR2 (0.37) PDE2ACES2KDM4EALDH1A1HPGD
SCHEMBL30740081 0.85 JAK2 (0.57) PDE2ACES2KDM4EALDH1A1HPGD
SCHEMBL1199588 0.85 JAK2 (0.57) PDE2ACES2KDM4EALDH1A1HPGD
SCHEMBL1818435 0.83 KDM4E (0.62) PDE2ACES2KDM4EALDH1A1HPGD
SCHEMBL11342078 0.83 CYP2C19 (0.49) KDM4EALDH1A1HPGDHSD17B10CYP2C19
SCHEMBL1455625 0.83 CES2 (0.52) PDE2ACES2KDM4EALDH1A1HPGD
SCHEMBL22407104 0.82 TLR8 (0.44) KDM4EALDH1A1HPGDHSD17B10USP2
SCHEMBL21852902 0.82 CES2 (0.55) CES2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL8493470 0.82 ALDH1A1 (0.48) PDE2ACES2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145596-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2025-05-08 US disclosed
EP-4476213-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-18 EP disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
CN-119072474-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2024-12-03 CN disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145596-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR PDE2A 156/4885CES2 3337/4885KDM4E 3629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.